China Expected to Approve Several Foreign Blockbuster Drugs in 2018
Foreign pharmaceutical giants Bristol-Myers Squibb, Novartis and AstraZeneca will win approval for some of their star products from China’s drug regulator in 2018, drug data provider PharmCube predicted in a recent report.
The approvals will pave the way for the drugmakers to further expand in one of the world’s largest drug markets, the report said.
Bristol-Myers’ cancer injection nivolumab is expected to be greenlighted in the first quarter, as China’s Center for Drug Evaluation began reviewing it in November, according to the report by the Beijing-based PharmCube.
- 1Update: China Demands Answers for Swedish Police’s ‘Brutal’ Treatment of Tourists
- 2China Could Ban Exports of Products Crucial to U.S. Manufacturers, Former Finance Minister Says
- 3 State-Owned Firms to Build $6.5 Billion Petrochemical Refinery in Alberta
- 4Trump Slaps New Tariffs on $200 Billion of Chinese Goods
- 5Merck Slashes Key Cancer Drug Price for China
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas